Medicenna Therapeutics (TSX:MDNA) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics Debt-to-Equity?

Medicenna Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Medicenna Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Medicenna Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$18.63 Mil. Medicenna Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Medicenna Therapeutics's Debt-to-Equity or its related term are showing as below:

During the past 9 years, the highest Debt-to-Equity Ratio of Medicenna Therapeutics was 1.79. The lowest was 0.00. And the median was 0.00.

TSX:MDNA's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Medicenna Therapeutics Debt-to-Equity Historical Data

The historical data trend for Medicenna Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics Debt-to-Equity Chart

Medicenna Therapeutics Annual Data

Trend

Dec15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

Medicenna Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Medicenna Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Medicenna Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medicenna Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's Debt-to-Equity falls into.

Medicenna Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Medicenna Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	29.486
	=	0.00

Medicenna Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	18.629
	=	0.00

Medicenna Therapeutics (TSX:MDNA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Medicenna Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicenna Therapeutics (TSX:MDNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MDNAF:USA

Address

2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2

Website

https://www.medicenna.com

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Executives

Albert George Beraldo	Director
Chandra Panchal	Director

Medicenna Therapeutics (TSX:MDNA) Headlines

No Headlines